Company Description
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample.
This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides.
In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents.
Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns.
The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions.
The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014.
10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Sep 12, 2019 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 1,178 |
| CEO | Serge Saxonov |
Contact Details
Address: 6230 Stoneridge Mall Road Pleasanton, California 94588-3260 United States | |
| Phone | 925 401 7300 |
| Website | 10xgenomics.com |
Stock Details
| Ticker Symbol | TXG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $39.00 |
| CIK Code | 1770787 |
| CUSIP Number | 88025U109 |
| ISIN Number | US88025U1097 |
| Employer ID | 45-5614458 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Serge Saxonov Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Benjamin J. Hindson Ph.D. | Co-Founder, President, Chief Scientific Officer and Director |
| Adam S. Taich | Chief Financial Officer, Treasurer, Principal Financial Officer and Principal Accounting Officer |
| Jim Goodrich | Chief of Global Operations |
| Michael Schnall-Levin Ph.D. | Founding Scientist and Chief Technology Officer |
| Cassie Corneau | Manager of Investor Relations and Strategic Finance |
| Dr. Randy Wu | General Counsel and Secretary |
| Mennah Moustafa | Chief Commercial Officer |
| Jens Durruthy | Associate Director of Product Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 144 | Filing |
| Feb 25, 2026 | 144 | Filing |
| Feb 23, 2026 | 144 | Filing |
| Feb 23, 2026 | 144 | Filing |
| Feb 23, 2026 | 144 | Filing |
| Feb 13, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 13, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 8, 2026 | SCHEDULE 13G/A | Filing |